Clinical trials recruiting for Small Cell Carcinoma
Fewer than 3 recruiting trials found.
2
Recruiting trials
5
US states with sites
14
Countries
50%
Accept healthy volunteers
Phase breakdown
Phase 3 1Not applicable 1
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| BL-M14D1 and Atezolizumab | 1 |
| Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Arkansas | 1 |
| California | 1 |
| Florida | 1 |
| New Jersey | 1 |
| Virginia | 1 |
Top cities
East Brunswick, New Jersey 1Fairfax, Virginia 1Glendale, California 1Long Beach, California 1Los Angeles, California 1Miami, Florida 1Springdale, Arkansas 1
Self-screener
Recruiting trials
- BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Related conditions
Trials recruiting for Small Cell Carcinoma often also study these conditions. Each links to its own recruiting-trial list.
Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Cancer Extensive Stage 14Small cell lung cancer 87SCLC,Extensive Stage 12Sclc 13Renal cell carcinoma 28Non-small cell lung cancer 507Melanoma 487Lung Cancer Metastatic 7Lung cancer 2180
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Small Cell Carcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.